Alba Tiley, head of sustainability at Centrient Pharmaceuticals discusses why a sustainable approach to developing antibiotics is key to combatting antimicrobial resistance (AMR).
Sustainability
Antimicrobial resistance (AMR) is the biggest health crisis of this and the next generation.
By 2050 AMR is predicted to cause 10 million global deaths per year, more than obesity and all cancers combined and it is anticipated to cost the global economy more than 100 trillion USD per year in lost GDP. Without effective antimicrobials for the prevention and treatment of infections, the success of critical medical procedures such as organ transplantation, chemotherapy and major surgery will be severely compromised.